Michael S. Brown Sells 1,500 Shares of Regeneron Pharmaceuticals Inc (REGN) Stock
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Director Michael S. Brown sold 1,500 shares of the company’s stock in a transaction dated Wednesday, August 22nd. The shares were sold at an average price of $380.49, for a total transaction of $570,735.00. Following the completion of the sale, the director now directly owns 1,500 shares of the company’s stock, valued at $570,735. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
NASDAQ REGN opened at $376.33 on Friday. The stock has a market cap of $41.08 billion, a P/E ratio of 23.10, a PEG ratio of 1.27 and a beta of 1.26. Regeneron Pharmaceuticals Inc has a 52-week low of $281.89 and a 52-week high of $505.49. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.62 and a quick ratio of 2.92.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $5.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.60 by $0.85. The firm had revenue of $1.61 billion during the quarter, compared to analysts’ expectations of $1.56 billion. Regeneron Pharmaceuticals had a net margin of 25.65% and a return on equity of 29.30%. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the company posted $4.17 earnings per share. sell-side analysts predict that Regeneron Pharmaceuticals Inc will post 19.4 EPS for the current fiscal year.
REGN has been the subject of a number of research reports. Canaccord Genuity reaffirmed a “$367.74” rating and issued a $304.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, July 19th. TheStreet raised shares of Regeneron Pharmaceuticals from a “c” rating to a “b-” rating in a report on Wednesday, July 25th. Credit Suisse Group set a $420.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, May 5th. Leerink Swann set a $435.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Friday, May 4th. Finally, BidaskClub raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 10th. Two research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $418.04.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Recommended Story: Market Capitalization and Individual Investors
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.